2-[4-(2-methoxy-ethyl)-piperazin-1-yl]-ethylamine | 1067659-06-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-[4-(2-methoxy-ethyl)-piperazin-1-yl]-ethylamine
• 英文别名: 2-(4-(2-Methoxyethyl)piperazin-1-yl)ethanamine；2-[4-(2-methoxyethyl)piperazin-1-yl]ethanamine
• CAS: 1067659-06-6
• 化学式: C₉H₂₁N₃O
• 分子量: 187.285
• InChiKey: AXRKRZWRJHGUQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  41.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-4-(6-(4-fluorophenyl)-5,6-dihydrobenzo[h]quinazolin-2-ylamino)phenethyl methanesulfonate 、 2-[4-(2-methoxy-ethyl)-piperazin-1-yl]-ethylamine 以 三乙胺 为溶剂， 生成 (S)-6-(4-fluorophenyl)-N-(4-(2-(4-(2-methoxyethyl)piperazin-1-yl)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine
  参考文献：
  名称：

  SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F]ISOQUINOLIN-2-AMINE COMPOUNDS

  摘要：

  本发明涉及取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物及其合成方法。本发明还涉及含有取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物的药物组合物，以及通过将这些化合物和药物组合物用于需要治疗细胞增殖性疾病的受试者来治疗癌症等细胞增殖性疾病的方法。

  公开号：

  US20100239525A1

文献信息

• 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases
  申请人：Boettcher Andreas

  公开号：US20100125064A1

  公开（公告）日：2010-05-20

  The invention relates to 3-heterocyclyl indolyl compounds capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively, said compounds having the formula I, wherein R 1 , R 2 , R 3 , R 4 , R A , Y and Y are as defined in the specification. Due to their activity, the compounds are useful in the treatment of various disorders and diseases mediated by the activity of MDM2 and/or MDM4, or variants thereof, such as inflammatory or proliferative diseases or in the protection of cells.

  本发明涉及能够抑制p53或其变体与MDM2和/或MDM4或其变体相互作用的3-杂环基吲哚化合物，其中所述化合物具有式I，其中R1、R2、R3、R4、RA、Y和Y的定义见说明书。由于其活性，这些化合物可用于治疗由MDM2和/或MDM4或其变体介导的各种疾病和疾病，例如炎症性或增殖性疾病或细胞保护。
• Substituted 5,6-dihydro-6-phenylbenzo[F]isoquinolin-2-amine compounds
  申请人：Ali Syed

  公开号：US08357694B2

  公开（公告）日：2013-01-22

  The present invention relates to substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

  本发明涉及取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物及其合成方法。本发明还涉及含有取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物的制药组合物，以及通过将这些化合物和制药组合物用于需要治疗细胞增殖性疾病，如癌症的受试者来治疗的方法。
• [EN] ANTIBACTERIAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIBACTÉRIENS
  申请人：FORGE THERAPEUTICS INC

  公开号：WO2022173756A1

  公开（公告）日：2022-08-18

  Provided herein are heterocyclic compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting the growth of gram-negative bacteria. The subject compounds and compositions are useful for the treatment of bacterial infections, such as pneumonia.

  本文提供了杂环化合物和包含这些化合物的药物组合物，用于抑制革兰氏阴性菌的生长。这些化合物和组合物对于治疗细菌感染，如肺炎，是有用的。
• Triterpene amine derivatives
  申请人：DFH THERAPEUTICS

  公开号：US11236122B2

  公开（公告）日：2022-02-01

  The present invention concerns novel pharmaceutically active triterpene amine derivatives, pharmaceutical compositions containing the same, their use as medicaments, and the use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the triterpene amine compounds. Specifically, the compounds are derivatives of betulinic acid having substitutions at one or more of the C-3, C-28 and C-19 positions as further described herein. The novel compounds are useful as antiretroviral agents. In particular, the novel compounds are useful for the treatment of Human Immunodeficiency Virus-1 (HIV-1).

  本发明涉及新型具有药用活性的三萜胺衍生物、含有三萜胺衍生物的药物组合物、其作为药物的用途，以及使用这些化合物制造特定药物。本发明还涉及一种涉及三萜胺化合物给药的治疗方法。具体来说，这些化合物是白桦脂酸的衍生物，在 C-3、C-28 和 C-19 位上有一个或多个取代位，如本文进一步描述的那样。这些新型化合物可用作抗逆转录病毒药物。特别是，这些新型化合物可用于治疗人类免疫缺陷病毒-1（HIV-1）。
• 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES
  申请人：Novartis AG

  公开号：EP2142535A2

  公开（公告）日：2010-01-13